A Prospective Observational Study on of Early-Onset Gastrointestinal Cancer: From Tumor Features to Patient Lifestyle Habits

NCT07479472 · tracked via the Priya Life Science Italy tracker

Sponsor

Gruppo Oncologico Italiano di Ricerca Clinica

Phase

Observational

Started

2026-04

Last updated

2026-03-18

Condition(s) studied

Early-onset Gastrointestinal Cancer

Investigational drug(s) / intervention(s)

to characterize the distinctive features of EO-GI cancer through a comprehensive approach that considers clinical and demographic factors, tumor features, and patient lifestyle habits

to characterize the distinctive features of EO-GI cancer through a comprehensive approach that considers clinical and demographic factors, tumor features, and patient lifestyle habits: to characterize the distinctive features of EO-GI cancer through a comprehensive approach that considers clinical and demographic factors, tumor features, and patient lifestyle habits, in a real-world Italian settings, mainly located in Northern Italy

Study summary

The YOGICO study aims to characterize the distinctive features of EoGI cancer through a holistic approach that integrates clinical and demographic data, tumor biological characteristics, and patient lifestyle habits

Eligibility

Sex

ALL

Min age

18 Years

Max age

49 Years

Healthy volunteers

Inclusion Criteria: * Provide a signed and dated informed consent form (ICF) * Willing to comply with all study procedures and be available for the duration of the study * Male or female, aged 18-49 years old at time of EoGI cancer diagnosis * Patients with newly diagnosed early-onset gastrointestinal cancer histologically confirmed: colorectal, gastroesophageal and pancreatic tumor site, regardless of histological type * Any disease stage, performance status, and type of treatment, including experimental therapies and supportive care * Previous or concomitant malignancies are allowed provided they do not involve the gastrointestinal tract Exclusion Criteria: * Cognitive, linguistic, or physical barriers that prevent a detailed reconstruction of the patient's personal medical history including past lifestyle habits * Having previously received any treatments directed at the newly diagnosed EOGI cancer (i.e., at the time of inclusion, the patient has not yet started any type of treatment, excluding surgery)

Primary outcome measure(s)

Primary outcome — One year from the enrollment
Describe clinical and tumor features of newly diagnosed EoGI cancer patients in a real-world Italian setting.

Trial sites (11)

Facility	City	Region
Oncologia, Ospedale Sant'Orsola	Bologna	BO
Istituto Romagnolo per lo studio dei tumori "Dino Amadori", IRCCS IRST	Meldola	FC
Oncologia Ospedale Carlo Poma di Mantova	Mantua	MN
Oncologia di Prossimità, Ospedale di Carpi e DHO Mirandola, Ausl Modena	Carpi	MO
Centro Oncologico Modenese, Azienda Policlinico Universitaria di Modena	Modena	MO
Oncologia Area Sud Ausl Modena	Sassuolo	MO
Oncologia Medica, AUSL Piacenza	Piacenza	PC
Oncologia, Azienda Ospedaliero Universitaria di Parma	Parma	PR
Oncologia Medica, CORE Azienda USL-IRCCS Reggio Emilia	Reggio Emilia	RE
Oncologia, Ospedale di Rimini	Rimini	RN
Oncologia, ASST SETTE LAGHI, Ospedale di Circolo	Varese	VA

More Gruppo Oncologico Italiano di Ricerca Clinica trials in Italy

Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) Recruiting

Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). Recruiting

Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients Recruiting

AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA Recruiting

XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07479472 on ClinicalTrials.gov ↗ ← All trials in Italy